{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:42:38Z","timestamp":1757544158303,"version":"3.41.0"},"publisher-location":"Cham","reference-count":58,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783031849879","type":"print"},{"value":"9783031849886","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-3-031-84988-6_3","type":"book-chapter","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T06:56:05Z","timestamp":1749452165000},"page":"41-55","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Conditioning Regimen Options"],"prefix":"10.1007","author":[{"given":"Zheng-Li","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"issue":"6","key":"3_CR1","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/bmt.2016.7","volume":"51","author":"U Anurathapan","year":"2016","unstructured":"Anurathapan U et al (2016) Hematopoietic stem cell transplantation for homozygous beta-thalassemia and beta-thalassemia\/hemoglobin E patients from haploidentical donors. Bone Marrow Transplant 51(6):813\u2013818","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"3_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.bbmt.2015.11.001","volume":"22","author":"J Apperley","year":"2016","unstructured":"Apperley J et al (2016) Haploidentical hematopoietic stem cell transplantation: a global overview comparing Asia, the European Union, and the United States. Biol Blood Marrow Transplant 22(1):23\u201326","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"3_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/ajh.24933","volume":"93","author":"Y Arai","year":"2018","unstructured":"Arai Y et al (2018) Improved prognosis with additional medium-dose VP16 to CY\/TBI in allogeneic transplantation for high risk ALL in adults. Am J Hematol 93(1):47\u201357","journal-title":"Am J Hematol"},{"issue":"11","key":"3_CR4","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1182\/blood-2016-08-693481","volume":"129","author":"A Bacigalupo","year":"2017","unstructured":"Bacigalupo A (2017) How I treat acquired aplastic anemia. Blood 129(11):1428\u20131436","journal-title":"Blood"},{"issue":"12","key":"3_CR5","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A et al (2009) Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 15(12):1628\u20131633","journal-title":"Biol Blood Marrow Transplant"},{"key":"3_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13045-014-0098-9","volume":"8","author":"F Baron","year":"2015","unstructured":"Baron F et al (2015) Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society. J Hematol Oncol 8:4","journal-title":"J Hematol Oncol"},{"issue":"3","key":"3_CR7","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41409-019-0702-2","volume":"55","author":"AH Bazarbachi","year":"2020","unstructured":"Bazarbachi AH et al (2020) Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party. Bone Marrow Transplant 55(3):595\u2013602","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"3_CR8","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1016\/S2352-3026(19)30157-7","volume":"7","author":"DW Beelen","year":"2020","unstructured":"Beelen DW et al (2020) Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14\/L): a randomised, non-inferiority, phase 3 trial. Lancet Haematol 7(1):e28\u2013e39","journal-title":"Lancet Haematol"},{"issue":"20","key":"3_CR9","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1182\/bloodadvances.2019000722","volume":"3","author":"N Bejanyan","year":"2019","unstructured":"Bejanyan N et al (2019) Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. Blood Adv 3(20):3123\u20133131","journal-title":"Blood Adv"},{"issue":"29","key":"3_CR10","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1200\/JCO.20.00150","volume":"38","author":"YJ Chang","year":"2020","unstructured":"Chang YJ et al (2020) Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: a multicenter, open-label, randomized controlled study. J Clin Oncol 38(29):3367\u20133376","journal-title":"J Clin Oncol"},{"issue":"6","key":"3_CR11","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.bbmt.2018.01.031","volume":"24","author":"P Chiusolo","year":"2018","unstructured":"Chiusolo P et al (2018) A modified post-transplant cyclophosphamide regimen, for unmanipulated haploidentical marrow transplantation, in acute myeloid leukemia: a multicenter study. Biol Blood Marrow Transplant 24(6):1243\u20131249","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"3_CR12","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.bbmt.2017.09.005","volume":"24","author":"SO Ciurea","year":"2018","unstructured":"Ciurea SO et al (2018) Haploidentical transplantation for older patients with acute myeloid leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 24(6):1232\u20131236","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"3_CR13","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/j.bbmt.2014.06.028","volume":"20","author":"J Clay","year":"2014","unstructured":"Clay J et al (2014) Nonmyeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia. Biol Blood Marrow Transplant 20(11):1711\u20131716","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"3_CR14","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1038\/s41409-022-01674-x","volume":"57","author":"R Devillier","year":"2022","unstructured":"Devillier R et al (2022) Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT. Bone Marrow Transplant 57(9):1421\u20131427","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"3_CR15","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1182\/bloodadvances.2020001729","volume":"4","author":"AE DeZern","year":"2020","unstructured":"DeZern AE et al (2020) Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide. Blood Adv 4(8):1770\u20131779","journal-title":"Blood Adv"},{"issue":"9","key":"3_CR16","doi-asserted-by":"publisher","first-page":"e660","DOI":"10.1016\/S2352-3026(22)00206-X","volume":"9","author":"AE DeZern","year":"2022","unstructured":"DeZern AE et al (2022) Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial. Lancet Haematol 9(9):e660\u2013e669","journal-title":"Lancet Haematol"},{"issue":"1","key":"3_CR17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/17474086.2016.1268048","volume":"10","author":"CL Ebens","year":"2017","unstructured":"Ebens CL, MacMillan ML, Wagner JE (2017) Hematopoietic cell transplantation in Fanconi anemia: current evidence, challenges and recommendations. Expert Rev Hematol 10(1):81\u201397","journal-title":"Expert Rev Hematol"},{"issue":"24","key":"3_CR18","doi-asserted-by":"publisher","first-page":"5536","DOI":"10.1182\/bloodadvances.2021005566","volume":"5","author":"JS Garcia","year":"2021","unstructured":"Garcia JS et al (2021) Adding venetoclax to fludarabine\/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active. Blood Adv 5(24):5536\u20135545","journal-title":"Blood Adv"},{"issue":"21","key":"3_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202200978","volume":"9","author":"H Guo","year":"2022","unstructured":"Guo H et al (2022) Multiomics analysis identifies SOCS1 as restraining T cell activation and preventing graft-versus-host disease. Adv Sci 9(21):e2200978","journal-title":"Adv Sci"},{"issue":"12","key":"3_CR20","first-page":"1517","volume":"89","author":"HX Jun","year":"2004","unstructured":"Jun HX, Jun CY, Yu ZX (2004) In vivo induction of T-cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor. Haematologica 89(12):1517\u20131524","journal-title":"Haematologica"},{"issue":"4","key":"3_CR21","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.bbmt.2017.11.025","volume":"24","author":"P Kebriaei","year":"2018","unstructured":"Kebriaei P et al (2018) Intravenous Busulfan compared with Total body irradiation pretransplant conditioning for adults with acute lymphoblastic leukemia. Biol Blood Marrow Transplant 24(4):726\u2013733","journal-title":"Biol Blood Marrow Transplant"},{"issue":"19","key":"3_CR22","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1200\/JCO.2016.70.7349","volume":"35","author":"N Kroger","year":"2017","unstructured":"Kroger N et al (2017) Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized phase III study of the EBMT (RICMAC trial). J Clin Oncol 35(19):2157\u20132164","journal-title":"J Clin Oncol"},{"issue":"19","key":"3_CR23","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1182\/blood-2012-03-417998","volume":"120","author":"C Li","year":"2012","unstructured":"Li C et al (2012) A novel conditioning regimen improves outcomes in beta-thalassemia major patients using unrelated donor peripheral blood stem cell transplantation. Blood 120(19):3875\u20133881","journal-title":"Blood"},{"issue":"1","key":"3_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14514","volume":"36","author":"F Lin","year":"2022","unstructured":"Lin F et al (2022) A modified conditioning regimen based on low-dose cyclophosphamide and fludarabine for haploidentical hematopoietic stem cell transplant in severe aplastic anemia patients at risk of severe cardiotoxicity. Clin Transpl 36(1):e14514","journal-title":"Clin Transpl"},{"issue":"2","key":"3_CR25","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41409-022-01865-6","volume":"58","author":"C Luo","year":"2023","unstructured":"Luo C et al (2023) Myeloablative conditioning regimens in adult patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation in complete remission: a systematic review and network meta-analysis. Bone Marrow Transplant 58(2):175\u2013185","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"3_CR26","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","volume":"14","author":"L Luznik","year":"2008","unstructured":"Luznik L et al (2008) HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 14(6):641\u2013650","journal-title":"Biol Blood Marrow Transplant"},{"key":"3_CR27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/978-3-030-02278-5_13","volume-title":"Conditioning, in the EBMT handbook: hematopoietic stem cell transplantation and cellular therapies","author":"A Nagler","year":"2019","unstructured":"Nagler A, Shimoni A (2019) In: Carreras E et al (eds) Conditioning, in the EBMT handbook: hematopoietic stem cell transplantation and cellular therapies. Springer, Cham, pp 99\u2013107"},{"issue":"28","key":"3_CR28","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1200\/JCO.2013.48.8114","volume":"31","author":"A Nagler","year":"2013","unstructured":"Nagler A et al (2013) Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen\u2013a report from the acute leukemia working party of the European group for blood and marrow transplantation. J Clin Oncol 31(28):3549\u20133556","journal-title":"J Clin Oncol"},{"issue":"8","key":"3_CR29","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/s41409-024-02282-7","volume":"59","author":"C Niederwieser","year":"2024","unstructured":"Niederwieser C et al (2024) Reduced intensity versus myeloablative conditioning for MDS: long-term results of an EBMT phase III study (RICMAC). Bone Marrow Transplant 59(8):1084\u20131091","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"3_CR30","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.bbmt.2008.06.020","volume":"14","author":"R Pasquini","year":"2008","unstructured":"Pasquini R et al (2008) HLA-matched sibling hematopoietic stem cell transplantation for fanconi anemia: comparison of irradiation and nonirradiation containing conditioning regimens. Biol Blood Marrow Transplant 14(10):1141\u20131147","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"3_CR31","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1200\/JCO.20.02529","volume":"39","author":"C Peters","year":"2021","unstructured":"Peters C et al (2021) Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study. J Clin Oncol 39(4):295\u2013307","journal-title":"J Clin Oncol"},{"issue":"6","key":"3_CR32","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/s41409-019-0773-0","volume":"55","author":"PH Prata","year":"2020","unstructured":"Prata PH et al (2020) Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT Severe Aplastic Anemia Working Party. Bone Marrow Transplant 55(6):1050\u20131058","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"3_CR33","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1002\/ajh.25225","volume":"93","author":"F Saraceni","year":"2018","unstructured":"Saraceni F et al (2018) Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia. Am J Hematol 93(10):1211\u20131219","journal-title":"Am J Hematol"},{"issue":"1","key":"3_CR34","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13045-019-0727-4","volume":"12","author":"F Saraceni","year":"2019","unstructured":"Saraceni F et al (2019) Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). J Hematol Oncol 12(1):44","journal-title":"J Hematol Oncol"},{"issue":"3","key":"3_CR35","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1182\/blood-2005-10-4165","volume":"108","author":"C Schmid","year":"2006","unstructured":"Schmid C et al (2006) Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 108(3):1092\u20131099","journal-title":"Blood"},{"issue":"11","key":"3_CR36","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","volume":"35","author":"BL Scott","year":"2017","unstructured":"Scott BL et al (2017) Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol 35(11):1154\u20131161","journal-title":"J Clin Oncol"},{"issue":"4","key":"3_CR37","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.bbmt.2019.12.725","volume":"26","author":"F Sora","year":"2020","unstructured":"Sora F et al (2020) Allogeneic hemopoietic stem cell transplants in patients with acute myeloid leukemia (AML) prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): a retrospective study. Biol Blood Marrow Transplant 26(4):698\u2013703","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"3_CR38","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/bjh.15438","volume":"182","author":"Q Sun","year":"2018","unstructured":"Sun Q et al (2018) Haploidentical haematopoietic stem cell transplantation for thalassaemia major based on an FBCA conditioning regimen. Br J Haematol 182(4):554\u2013558","journal-title":"Br J Haematol"},{"key":"3_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.639502","volume":"11","author":"YQ Sun","year":"2021","unstructured":"Sun YQ et al (2021) Haploidentical stem cell transplantation with a novel conditioning regimen in older patients: a prospective single-arm phase 2 study. Front Oncol 11:639502","journal-title":"Front Oncol"},{"issue":"3","key":"3_CR40","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41409-021-01550-0","volume":"57","author":"R Swoboda","year":"2022","unstructured":"Swoboda R et al (2022) Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant 57(3):399\u2013406","journal-title":"Bone Marrow Transplant"},{"issue":"16","key":"3_CR41","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1182\/bloodadvances.2020001648","volume":"4","author":"HJ Symons","year":"2020","unstructured":"Symons HJ et al (2020) Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults. Blood Adv 4(16):3913\u20133925","journal-title":"Blood Adv"},{"issue":"25","key":"3_CR42","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.1182\/blood-2015-02-627786","volume":"125","author":"Y Wang","year":"2015","unstructured":"Wang Y et al (2015) Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood 125(25):3956\u20133962","journal-title":"Blood"},{"issue":"10","key":"3_CR43","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1038\/leu.2016.110","volume":"30","author":"Y Wang","year":"2016","unstructured":"Wang Y et al (2016) Haploidentical transplant for myelodysplastic syndrome: registry-based comparison with identical sibling transplant. Leukemia 30(10):2055\u20132063","journal-title":"Leukemia"},{"issue":"3","key":"3_CR44","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41409-018-0283-5","volume":"54","author":"L Wang","year":"2019","unstructured":"Wang L et al (2019) Clinical outcome of FLAG-IDA chemotherapy sequential with Flu-Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes. Bone Marrow Transplant 54(3):458\u2013464","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"3_CR45","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1007\/s11427-019-1610-2","volume":"63","author":"Y Wang","year":"2020","unstructured":"Wang Y et al (2020) Impact of prophylactic\/preemptive donor lymphocyte infusion and intensified conditioning for relapsed\/refractory leukemia: a real-world study. Sci China Life Sci 63(10):1552\u20131564","journal-title":"Sci China Life Sci"},{"issue":"24","key":"3_CR46","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1016\/j.scib.2021.06.002","volume":"66","author":"Y Wang","year":"2021","unstructured":"Wang Y et al (2021) Optimizing antithymocyte globulin dosing in haploidentical hematopoietic cell transplantation: long-term follow-up of a multicenter, randomized controlled trial. Sci Bull 66(24):2498\u20132505","journal-title":"Sci Bull"},{"key":"3_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.101035","volume":"62","author":"ZL Xu","year":"2023","unstructured":"Xu ZL, Huang XJ (2023) Haploidentical transplants with a G-CSF\/ATG-based protocol: experience from China. Blood Rev 62:101035","journal-title":"Blood Rev"},{"issue":"2","key":"3_CR48","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/bjh.14225","volume":"175","author":"LP Xu","year":"2016","unstructured":"Xu LP et al (2016) Haplo-identical transplantation for acquired severe aplastic anaemia in a multicentre prospective study. Br J Haematol 175(2):265\u2013274","journal-title":"Br J Haematol"},{"issue":"1","key":"3_CR49","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13045-018-0564-x","volume":"11","author":"L Xu","year":"2018","unstructured":"Xu L et al (2018) The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology. J Hematol Oncol 11(1):33","journal-title":"J Hematol Oncol"},{"issue":"2","key":"3_CR50","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14160","volume":"35","author":"ZL Xu","year":"2021","unstructured":"Xu ZL et al (2021) The incidence, clinical outcome, and protective factors of mixed chimerism following hematopoietic stem cell transplantation for severe aplastic anemia. Clin Transpl 35(2):e14160","journal-title":"Clin Transpl"},{"issue":"7","key":"3_CR51","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1038\/s41409-022-01682-x","volume":"57","author":"LP Xu","year":"2022","unstructured":"Xu LP et al (2022a) Bulsufan decreases the incidence of mixed chimaerism in HLA-matched donor transplantation for severe aplastic anaemia. Bone Marrow Transplant 57(7):1204\u20131206","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"3_CR52","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.scib.2022.01.024","volume":"67","author":"LP Xu","year":"2022","unstructured":"Xu LP et al (2022b) Long-term follow-up of haploidentical transplantation in relapsed\/refractory severe aplastic anemia: a multicenter prospective study. Sci Bull 67(9):963\u2013970","journal-title":"Sci Bull"},{"issue":"12","key":"3_CR53","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.3324\/haematol.2022.280758","volume":"107","author":"ZL Xu","year":"2022","unstructured":"Xu ZL et al (2022c) Comparable long-term outcomes between upfront haploidentical and identical sibling donor transplant in aplastic anemia: a national registry-based study. Haematologica 107(12):2918\u20132927","journal-title":"Haematologica"},{"issue":"3","key":"3_CR54","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/bjh.18408","volume":"199","author":"L Xu","year":"2022","unstructured":"Xu L et al (2022d) Unmanipulated haploidentical haematopoietic cell transplantation with radiation-free conditioning in Fanconi anaemia: a retrospective analysis from the Chinese Blood and Marrow Transplantation Registry Group. Br J Haematol 199(3):401\u2013410","journal-title":"Br J Haematol"},{"issue":"1","key":"3_CR55","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41409-022-01838-9","volume":"58","author":"L Xu","year":"2023","unstructured":"Xu L et al (2023) Fludarabine- and low-dose cyclophosphamide-based conditioning regimens provided favorable survival and engraftment for unmanipulated hematopoietic cell transplantation from unrelated donors and matched siblings in patients with Fanconi anemia: results from the CBMTR. Bone Marrow Transplant 58(1):106\u2013108","journal-title":"Bone Marrow Transplant"},{"key":"3_CR56","doi-asserted-by":"publisher","unstructured":"Xu ZL et al (2024) Clinical outcomes of three haploidentical transplantation protocols for hematologic malignancies based on data from the Chinese Bone Marrow Transplantation Registry Group. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2024.286040","DOI":"10.3324\/haematol.2024.286040"},{"issue":"1","key":"3_CR57","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13045-021-01159-2","volume":"14","author":"XH Zhang","year":"2021","unstructured":"Zhang XH et al (2021) The consensus from the Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. J Hematol Oncol 14(1):145","journal-title":"J Hematol Oncol"},{"issue":"2","key":"3_CR58","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1200\/JCO.22.00767","volume":"41","author":"H Zhang","year":"2023","unstructured":"Zhang H et al (2023) Busulfan plus cyclophosphamide versus total body irradiation plus cyclophosphamide for adults acute B lymphoblastic leukemia: an open-label, multicenter, phase III trial. J Clin Oncol 41(2):343\u2013353","journal-title":"J Clin Oncol"}],"container-title":["Advances in Experimental Medicine and Biology","Clinical Management of Challenges in Allogeneic Stem Cell Transplant"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-84988-6_3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T16:03:30Z","timestamp":1749485010000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-84988-6_3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9783031849879","9783031849886"],"references-count":58,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-84988-6_3","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"10 June 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}